Eli Lilly and Company Stock News

Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs.

In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a novel composite outcome defined by simultaneous symptomatic, endoscopic and histologic remission, biomarker normalization and no corticosteroid use In VIVID-1, one in five (20.4%) Omvoh-treated patients with Crohn's disease achieved corticosteroid-free deep remissi...

Exploratory data presented at Fall Clinical 2026 showed broader biomarker changes with Taltz and Zepbound vs. Taltz alone as early as Week 12 in first-of-its-kind TOGETHER-PsO study INDIANAPOLIS, Oct. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new exploratory data from the TOGETHER-PsO Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) an...

The healthcare sector stood out as one of the few bright spots in Wednesday's trading.

Eli Lilly's experimental cancer treatment, olomorasib, receives orphan drug designation from the Food and Drug Administration.

Gate Bioscience said on Monday it expanded a research and licensing ​agreement with Eli Lilly to develop ‌treatments targeting disease-causing proteins, in a deal potentially worth more than $870 million.

Although not always easy to quantify, intangible assets are one of the primary sources of strong competitive advantages for businesses and a key source of economic moats. Key Takeaways Intangible assets, including patents, brand equity, customer relationships, and proprietary technology, are non-physical but often the most powerful drivers of a company's competitive advantage.

INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocy...